July 2025
RFK Jr. Removes Top HHS Aides in Major Leadership Shakeup
RFK Jr.; Health and Human Services; leadership reshuffle; chief of staff; Matt Buckham; Heather Flick Melanson; Hannah Anderson; Trump loyalists; policy shakeup
Outsmarting Data Bottlenecks in Pharma: The Clinical Terminology Advantage
data bottlenecks; clinical terminology; pharmaceutical industry; data integration; interoperability; regulatory compliance; AI in pharma; patient outcomes
Otsuka Inks $613M Deal for Cantargia’s Autoimmune Antibodies
Otsuka Pharmaceutical; Cantargia; autoimmune diseases; IL1RAP antibodies; CAN10; biotech deal; hidradenitis suppurativa; systemic sclerosis; milestone payments; global commercialization
Vertex, NHS England Finalize Reimbursement Deal for CF Drug Alyftrek
Vertex; NHS England; Alyftrek; cystic fibrosis; reimbursement agreement; triple therapy; CFTR gene mutation; NICE; UK healthcare
Recent Developments in Building Measurable Patient Support Programs (2025)
patient support programs; measurable outcomes; collaborative healthcare; 2025 trends; Medicare reforms; cost efficiency; access to care
FDA Flags Eye Safety Concerns as GSK Seeks Blenrep’s US Return
GSK; Blenrep; FDA; eye safety; ocular toxicity; advisory committee; multiple myeloma; drug approval; United States; relapsed/refractory multiple myeloma
Veru Survey Highlights Muscle Loss Concerns Among GLP-1 Users as Lean Mass-Preserving Drug Advances
Veru; GLP-1 receptor agonists; muscle loss; enobosarm; lean mass; obesity; survey; older adults; high-protein diet
Sino Biopharm Acquires Merck’s PD-1xVEGF Bispecific Partner LaNova for up to $951M
Sino Biopharm; LaNova Medicines; acquisition; Merck; PD-1xVEGF bispecific antibody; cancer therapy; Chinese pharma; $951 million deal
Advancements in Predicting Tumor Response and Expanding Therapy Eligibility Using Epigenomic Biomarkers
epigenomic biomarkers; tumor response prediction; personalized cancer therapy; DNA methylation; AI-driven diagnostics
FDA Chief Calls for Lower User Fees as PDUFA VIII Negotiations Begin
FDA; user fees; PDUFA VIII; regulatory policy; drug approval; fee structure; negotiations